| Investment Case | |
| EdiGene | |
| Hua Dao Biotech | |
| Innolife | |
| Human Longevity | |
|
EdiGene is a genome-editing company, possessing efficient genome-editing techniques, advanced high-through put genetic screening platform, and ready-made knock-out cell lines. EdiGene is focusing on application of gene editing technology, including knock-out, inserting and targeted mutation and to develop new therapeutics for cancers, genetic diseases and infectious disease. http://edigene.com/ |
|
Shanghai Hua Dao Biotech Inc. （华道生物）is a development stage biotech company with a focus on CAR-T therapy (Chimeric Antigen Receptor T-Cell Therapy). Its anti-CD-19 CAR-T therapy has accumulated rich patient cases and affiliated patents and know-how. The company is prepared to submit is IND application in China in 2018. |
|
Chengdu Innolife is a successful company in the translational medicine field. Currently, the company achieved the self-regeneration of ischemic damage tissue through the reactivation of tissue injury signaling system, and mobilization of the body's inherent repair capability, that fundamentally solved the current medical bottleneck of incurable human ischemic injury organs. The company has filed a series of patents surrounding the topic. It plans to open a Phase-II clinical trial in the USA soon. |
|
Human Longevity,TMInc. (HLI) is the genomics-based, health intelligence company creating the world’s largest and most comprehensive database of whole genome, phenotype and clinical data. HLI is developing and applying large scale computing and machine learning to make novel discoveries from these data to generate personalized health insights. Our goal is to extend healthy human life by revolutionizing human health and transforming the practice of medicine. （From HLI Factsheet） HLI is founded by J. Craig Venter, PhD, regarded as one of the leading scientists of the 21st century for his numerous invaluable contributions to genomic research. https://www.humanlongevity.com/ |